Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SGT-53 |
| Trade Name | |
| Synonyms | transferrin receptor-targeted liposomal p53 cDNA|Synerlip p53 |
| Drug Descriptions |
SGT-53 is a cationic liposomal complex that is linked to an antibody targeting the transferrin receptor (Tff) and contains wild-type Tp53 plasmid, thereby delivering wild-type Tp53 to tumor cells expressing Tff and potentially restoring wild-type Tp53 activity (PMID: 23470564, PMID: 27357628, PMID: 31241175) |
| DrugClasses | p53 Gene Therapy 4 |
| CAS Registry Number | NA |
| NCIT ID | C29474 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Irinotecan + SGT-53 + Temozolomide | Bevacizumab Irinotecan SGT-53 Temozolomide | 0 | 1 |
| Carboplatin + Pembrolizumab + SGT-53 | Carboplatin Pembrolizumab SGT-53 | 0 | 1 |
| Cyclophosphamide + SGT-53 + Topotecan | Cyclophosphamide SGT-53 Topotecan | 0 | 1 |
| Docetaxel + SGT-53 | Docetaxel SGT-53 | 0 | 0 |
| Nivolumab + SGT-53 | Nivolumab SGT-53 | 0 | 1 |
| SGT-53 | SGT-53 | 0 | 2 |